Simplify Logo

Full-Time

Senior Director

NGS Liquid Biopsy

Posted on 3/29/2024

Tempus

Tempus

1,001-5,000 employees

AI-enabled precision medicine and analytics

Data & Analytics
Hardware
AI & Machine Learning
Financial Services
Biotechnology
Healthcare

Senior

Chicago, IL, USA

Category
Bioinformatics
Genomics
Biology & Biotech
Requirements
  • Master’s with 15+ years or Ph.D. with 10+ years’ experience in life science, molecular diagnostics, or a related field
  • Deep technical understanding of NGS assays and sequencer platforms
  • Specific experience with high-sensitivity NGS applications suitable for liquid biopsy applications
  • Experience with liquid biopsy applications in oncology from plasma-derived cf/ctDNA and/or CTCs
  • Experience in developing clinical assays and understanding of regulatory guidelines
  • Experience leading small teams in a fast-paced environment
  • Ability to work closely with cross-functional team leads
  • Strong track record of assay and/or product development
Responsibilities
  • Lead an assay development team from project inception through launch
  • Ensure projects are completed within aggressive timelines
  • Facilitate smooth transfers of developed workflows into clinical lab environments
  • Evaluate emerging molecular and sequencing technologies
  • Mentor project leads and scientific staff
  • Provide support for other activities in the clinical Next Generation Sequencing lab

Tempus specializes in AI-enabled precision medicine, utilizing data and artificial intelligence to accelerate the discovery of novel targets, predict treatment effectiveness, identify clinical trials, and diagnose diseases earlier. The company's analytical machine learning platform leverages expansive clinical and molecular data to enable real-time, data-driven decisions for personalized care and targeted therapies.

Company Stage

Series G

Total Funding

$1.3B

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

8%

1 year growth

12%

2 year growth

38%
INACTIVE